Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 4Active not recruiting 2Withdrawn 1Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Gynecologic 1Breast 1

Conditions

Breast Neoplasms 20Ovarian Neoplasms 19Fallopian Tube Neoplasms 9Prostatic Neoplasms 7Triple Negative Breast Neoplasms 6Neoplasm Metastasis 6Small Cell Lung Carcinoma 4Pancreatic Neoplasms 4Metastatic Castration-resistant Prostate Cancer 4Squamous Cell Carcinoma of Head and Neck 3Lung Neoplasms 3Glioma 3Endometrial Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Solid Tumors 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Osteosarcoma 2Neoplasms 2Glioblastoma 2Cholangiocarcinoma 2Carcinosarcoma 2Carcinoma, Endometrioid 2Xanthogranuloma, Juvenile 1Wilms Tumor 1Urinary Bladder Neoplasms 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1

Interventions

Oxaliplatin 21pembrolizumab 17Capecitabine 15Nivolumab 13Paclitaxel 12Fluorouracil 12Leucovorin 11Docetaxel 10atezolizumab 7Trastuzumab 7tislelizumab 5Ramucirumab 5durvalumab 4Standard of Care 4Magnetic Resonance Spectroscopy 4Irinotecan 4Cisplatin 4Carboplatin 4zolbetuximab 3zimberelimab 3apatinib 3Specimen Handling 3S 1 (combination) 3Gemcitabine 3Bevacizumab 3trifluridine tipiracil drug combination 2tremelimumab 2trastuzumab deruxtecan 2relatlimab 2osimertinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Stomach Neoplasms × olaparib × Clear all
NCT02734004 2026-04-20

MEDIOLA

AstraZeneca

Phase 1/2 Active not recruiting
264 enrolled 32 charts
BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT04209686 2025-12-03

Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Active not recruiting
36 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡